优化对低强度脉冲超声波的辐射条件,以提高内皮氧化合成酶的调节
Daiki Ouchi1, Shohei Mori1, Mototaka Arakawa2,3
1Graduate School of Engineering, Tohoku University, 6-6-05 Aoba, Aramaki, Aoba-Ku, Sendai, Miyagi, 980-8579, Japan.
Journal of medical ultrasonics (2001)
|December 5, 2023
概括
低强度脉冲超声波 (LIPUS) 治疗显示出通过增强血管生长来治疗缺血性心脏病的潜力. 这项研究确定了低于最佳的超声波条件,以促进内皮氧化合成酶 (eNOS) 表达.
科学领域:
- 心血管研究研究心血管研究
- 生物医学工程 生物医学工程
- 再生医学是一种再生医学.
背景情况:
- 缺血性心脏病仍然是全球死亡的主要原因.
- 目前用于心肌缺血的治疗方法存在局限性.
- 低强度脉冲超声波 (LIPUS) 治疗是一种有前途的微创疗法.
研究的目的:
- 开发一种使用LIPUS.LIPUS治疗缺血性心脏病的微创治疗方法.
- 通过血管生成证明LIPUS疗法在改善心肌缺血的疗效.
- 为了确定促进内皮氧化合成酶 (eNOS) 表达的最佳LIPUS参数.
主要方法:
- 研究了五个关键的超声波辐射参数.
- 利用人类冠状动脉内皮细胞 (HCAEC) 来评估eNOS表达.
- 定义了一个新的指数,功率×总循环,以将LIPUS参数与eNOS表达式相关联.
主要成果:
- 确定了低于最佳的LIPUS条件,包括1MHz频率,500kPa声压,20分钟持续时间,32-48微秒脉冲持续时间和320微秒脉冲重复时间.
- 使用拟议的索引,证明了 LIPUS 参数与 eNOS 表达式之间的统一关系.
- 建立了优化LIPUS治疗心肌血管生成的基础.
结论:
- 确定了低于最佳的超声波照射条件,以促进HCAEC中的eNOS表达.
- 提供了LIPUS参数和血管生成分子表达之间的关系的见解.
- 奠定了进一步研究心血管应用LIPUS优化的基础.
相关概念视频
Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Nuclear Overhauser Enhancement (NOE)
701
Irradiation of a spin-active nucleus causes an increase or decrease in the signal intensity of neighboring nuclei that are not necessarily chemically bonded or involved in J-coupling. This phenomenon, called the Nuclear Overhauser Enhancement (NOE), results from through-space interactions between the nuclear spins. The NOE effect decreases with increasing internuclear distance and is generally not observed beyond 4 angstroms. In NOE, dipole-dipole interactions between neighboring...
701
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188


